Future of Anticoagulant Therapy

Cardiovascular Therapeutics

Volumn 29, Issue 5, 2011, Pages 291-300

  Harenberg, Job ^a   Wehling, Martin ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Coagulation inhibitors; Coagulation thrombosis; Factor Xa inhibitors; Thrombin inhibitors

Indexed keywords

2 [4 [(1 ACETIMIDOYL 3 PYRROLIDINYL)OXY]PHENYL] 3 (7 AMIDINO 2 NAPHTHYL)PROPIONIC ACID; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; APIXABAN; AZD 0837; BETRIXABAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; CLOPIDOGREL; DABIGATRAN; DABIGATRAN ETEXILATE; DAREXABAN; EDOXABAN; ENOXAPARIN; EPTIFIBATIDE; FONDAPARINUX; HEPARIN; IDRABIOTAPARINUX; IDRAPARINUX; LOW MOLECULAR WEIGHT HEPARIN; NONSTEROID ANTIINFLAMMATORY AGENT; OTAMIXABAN; PHENPROCOUMON; PLACEBO; RIVAROXABAN; SEMULOPARIN; SR 123781; THROMBIN INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; WARFARIN; XIMELAGATRAN;

ACUTE CORONARY SYNDROME; ACUTE UNSTABLE ANGINA; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTICOAGULANT THERAPY; ANTICOAGULATION; BLEEDING; COMPARATIVE STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DEEP VEIN THROMBOSIS; DRUG BLOOD LEVEL; DRUG COST; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG SAFETY; EMBOLISM; FUTUROLOGY; HEALTH CARE COST; HEALTH CARE SYSTEM; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HUMAN; LOW DRUG DOSE; LUNG EMBOLISM; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; NONHUMAN; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT; STROKE; SYSTEMIC THERAPY; THROMBOSIS PREVENTION; UNSTABLE ANGINA PECTORIS; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; BLOOD COAGULATION; COST-BENEFIT ANALYSIS; DRUG COSTS; FACTOR XA; FIBRINOLYTIC AGENTS; HUMANS; THROMBIN; THROMBOEMBOLISM; TREATMENT OUTCOME;

EID: 80053144572     PISSN: 17555914     EISSN: 17555922     Source Type: Journal    
DOI: 10.1111/j.1755-5922.2010.00198.x     Document Type: Review

References (51)

1. Hirsh J, O'Donnell M, Eikelboom JW. Beyond unfractionated heparin and warfarin: Current and future advances. Circulation 2007;116:552-560.
2. Saiah E, Soares C. Small molecule coagulation cascade inhibitors in the clinic. Curr Top Med Chem 2005;5:1677-1695.
3. Bauer KA. New anticoagulants. Curr Opin Hematol 2008;15:509-515.
4. Ma Q, Fareed J. Idraparinux sodium. Sanofi-Aventis. IDrugs 2004;7:1028-1034.
5. The van Gogh Investigators. Idraparinux versus standard therapy for venous thromboembolic disease. N Engl J Med 2007;357:1094-1104.
6. The van Gogh Investigators. Extended prophylaxis of venous thromboembolism with idraparinux. N Engl J Med 2007;357:1105-1112.
7. Amadeus Investigators; Bousser MG, Bouthier J, Büller HR, et al. Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: A randomised, open-label, non-inferiority trial. Lancet 2008;371:315-321.
8. Harenberg J, Jörg I, Vukojevic Y, Mikus G, Weiss C. Anticoagulant effects of Idraparinux after termination of therapy for prevention of recurrent venous thromboembolism: Observations from the van Gogh trials. Eur J Clin Pharmacol 2008;64:555-563.
9. Harenberg J. Development of idraparinux and idrabiotaparinux for anticoagulant therapy. Thromb Haemost 2009;102:811-815.
10. Lassen MR, Dahl OE, Mismetti P, Destrée D, Turpie AG. AVE5026, a new hemisynthetic ultra-low-molecular weight heparin for the prevention of venous thromboembolism in patients after total knee replacement surgery-TREK: A dose-ranging study. J Thromb Haemost 2009;7:566-572.
11. de Kort M, Buijsman RC, van Boeckel CA. Synthetic heparin derivatives as new anticoagulant drugs. Drug Discov Today 2005;10:769-779.
12. Lassen MR, Dahl O, Mismetti P, Zielske D, Turpie AG. SR123781A: A new once-daily synthetic oligosaccharide anticoagulant for thromboprophylaxis after total hip replacement surgery: The DRIVE (Dose Ranging Study in Elective Total Hip Replacement Surgery) study. J Am Coll Cardiol 2008;51:1498-1504.
13. Harenberg J. Development of new anticoagulants: Present and future. Semin Thromb Hemost 2008;34:779-793.
14. Cohen M, Bhatt DL, Alexander JH, et al.; on behalf of the SEPIA-PCI Trial Investigators. Randomized, double-blind, dose-ranging study of otamixaban, a novel, parenteral, short-acting direct factor xa inhibitor, in percutaneous coronary intervention: The SEPIA-PCI Trial. Circulation 2007;115:2642-2651.
15. Sabatine MS, Antman EM, Widimsky P, et al. Otamixaban for the treatment of patients with non-ST-elevation acute coronary syndromes (SEPIA-ACS1 TIMI 42): A randomised, double-blind, active-controlled, phase 2 trial. Lancet 2009;374:787-795.
16. Rezaie AR. DX-9065a inhibition of factor Xa and the prothrombinase complex: Mechanism of inhibition and comparison with therapeutic heparins. Thromb Haemost 2003;89:112-121.
17. Alexander JH, Yang H, Becker RC, et al.; on behalf of the XANADU-ACS Investigators. First experience with direct, selective factor Xa inhibition in patients with non-ST-elevation acute coronary syndromes: Results of the XANADU-ACS trial. J Thromb Haemost 2005;3:439-447.
18. Kubitza D, Haas S. Novel factor Xa inhibitors for prevention and treatment of thromboembolic diseases. Expert Opin Investig Drugs 2006;15:843-855.
19. Garcia D, Libby E, Crowther MA. The new oral anticoagulants. Blood 2010;115:15-20.
20. Agnelli G, Gallus A, Goldhaber SZ, et al.; for the ODIXa-DVT Study Investigators. Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): The ODIXa-DVT Study. Circulation 2007;116:180-187.
21. Büller HR, Lensing AW, Prins MH, et al. Einstein-DVT Dose-Ranging Study investigators. A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: The Einstein-DVT Dose-Ranging Study. Blood 2008;112:2242-2247.
22. Büller HR; on behalf of the Einstein Investigators. Once daily rivaroxaban versus placebo in the long-term prevention of recutrent symptomatic venous thromboembolism, the Einstein-Extension study. Blood 2009;(Suppl) [Abstract LBA2 Blood].
23. ROCKET AF Study Investigators. Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: Rationale and design of the ROCKET AF study. Am Heart J 2010;159:340-347.
24. Mega JL, Braunwald E, Mohanavelu S, et al.; ATLAS ACS-TIMI 46 Study Group. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): A randomised, double-blind, phase II trial. Lancet 2009;374:29-38.
25. Pinto DJ, Orwat MJ, Koch S, et al. Discovery of 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4, 5, 6, 7-tetrahydro-1H-pyrazolo[, -c]pyridine-3-carboxamide (Apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa34. J Med Chem 2007;50:5339-5356.
26. Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Portman RJ. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med 2009;361:594-604.
27. Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Hornick P; ADVANCE-2 Investigators. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): A randomised double-blind trial. Lancet 2010;375:807-815.
28. Botticelli Investigators; Writing Committee; Buller H, Deitchman D, Prins M, Segers A. Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study. J Thromb Haemost 2008;6:1313-1318.
29. Alexander JH, Becker RC, Bhatt DL, et al.; APPRAISE Steering Committee and Investigators. Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: Results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. Circulation 2009;119:2877-2885.
30. Lopes RD, Alexander JH, Al-Khatib SM, et al. ; on behalf of the ARISTOTLE Investigators. Apixaban for Reduction In Stroke and Other ThromboemboLic Events in Atrial Fibrillation (ARISTOTLE) trial: Design and rationale. Am Heart J 2010;159:331-339.
31. Eikelboom JW, O'Donnell M, Yusuf S, et al. Rationale and design of AVERROES: Apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment. Am Heart J 2010;159:348-353.
32. Turpie AG, Bauer KA, Davidson BL, et al.; EXPERT Study Group. A randomized evaluation of betrixaban, an oral factor Xa inhibitor, for prevention of thromboembolic events after total knee replacement (EXPERT). Thromb Haemost 2009;101:68-76.
33. Eriksson BI, Turpie AG, Lassen MR, et al.; for the ONYX STUDY GROUP. A dose escalation study of YM150, an oral direct factor Xa inhibitor, in the prevention of venous thromboembolism in elective primary hip replacement surgery. J Thromb Haemost 2007;5:1660-1665.
34. Agnelli G, Haas SK, Krueger KA, et al. A phase II study of the safety and efficacy of a novel oral fXa inhibitor (LY517717) for the prevention of venous thromboembolism following TKR or THR. J Thromb Haemost 2007;5:746-753.
35. Zafar MU, Vorchheimer DA, Gaztanaga J, et al. Antithrombotic effects of factor Xa inhibition with DU-176b: Phase-I study of an oral, direct factor Xa inhibitor using an ex-vivo flow chamber. Thromb Haemost 2007;98:883-888.
36. Ogata K, Mendell-Harary J, Tachibana M, Matsumoto H, Oguma T, Kojima M, Kunitada S. Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers. J Clin Pharmacol 2010. doi.
37. Linkins LA, Weitz JI. Pharmacology and clinical potential of direct thrombin inhibitors. Curr Pharm Des 2005;11:3877-3884.
38. Harenberg J, Jörg I, Weiss C. Incidence of recurrent venous thromboembolism of patients after termination of treatment with ximelagatran. Eur J Clin Pharmacol 2006;62:173-177.
39. Gurewich V. Ximelagatran Promises and concerns. JAMA 2005;29:736-739.
40. Harenberg J, Jörg I, Weiss C. Observations of alanine aminotransferase and aspratate aminotransferase in THRIVE studies treated orally with ximelagatran. Int J Toxicol 2006;25:163-169.
41. Lee WM, Larrey D, Olsson R, et al. Hepatic findings in long-term clinical trials of ximelagatran. Drug Saf 2005;28:351-370.
42. Stangier K, Rathgen H, Staehle D, et al. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol 2007;64:292-303.
43. Eriksson BI, Dahl OE, Buller HR, et al. A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: The BISTRO II randomized trial. J Thromb Haemost 2005;3:103-111.
44. Schulman S, Kearon C, Kakkar AK, et al.; RE-COVER Study Group. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009;361:2342-2352.
45. Ezekowitz MD, Reilly PA, Nehmiz G, et al. Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study). Am J Cardiol 2007;100:1419-1426.
46. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1-13.
47. Olsson SB, Rasmussen LH, Tveit A, Jensen E, Wessman P, Panfilov S, Wahlander K. Safety and tolerability of an immediate-release formulation of theoral direct thrombin inhibitor AZD0837 in the prevention of stroke and systemic embolism in patients with atrial fibrillation. Thromb Haemost 2010;103:604-612.
48. Srivastava A, Hudson M, Hamoud I, Cavalcante J, Pai C, Kaatz S. Examining warfarin underutilization rates in patients with atrial fibrillation: Contraindications detailed chart review essential to capture to warfarin therapy. Thromb J 2008;6:6-12.
49. Wolowacz SE, Roskell NS, Plumb JM, et al. Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism in patients aged over 75 years or with moderate renal impairment undergoing total knee or hip replacement. Thromb Haemost 2010;103:360-371.
50. Holmes M, Carroll C, Papaioannou D. Dabigatran etexilate for the prevention of venous thromboembolism in patients undergoing elective hip and knee surgery: A single technology appraisal. Health Technol Assess 2009;13(Suppl 2):55-62.
51. Martí-Fàbregas J, Mateo J. Old and new anticoagulant agents for the prevention and treatment of patients with ischemic stroke. Cerebrovasc Dis 2009;27(Suppl 1):111-119.